NCT07213154 Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions
| NCT ID | NCT07213154 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Malignant Skin Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-10-15 |
| Primary Completion | 2026-09-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2025-10-15 with a primary completion date of 2026-09-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial studies how well an optical imaging scan called quantitative oblique back-illumination microscopy (qOBM) helps in diagnosing skin cancer in patients with skin lesions. qOBM is a non-invasive procedure that uses red light for illumination, and may work better than no imaging procedures in aiding doctors in diagnosing skin lesions.
Eligibility Criteria
Inclusion Criteria: * Male or Female * Candidate with skin lesions * Signed study-specific informed consent prior to study entry * ≥ 18 years old Exclusion Criteria: * Prior surgery or radiotherapy to the area to be treated
Contact & Investigator
Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR
PRINCIPAL INVESTIGATOR
Emory University Hospital/Winship Cancer Institute
Frequently Asked Questions
Who can join the NCT07213154 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Skin Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07213154 currently recruiting?
Yes, NCT07213154 is actively recruiting participants. Contact the research team at m.k.khan@emory.edu for enrollment information.
Where is the NCT07213154 trial being conducted?
This trial is being conducted at Atlanta, United States, Atlanta, United States.
Who is sponsoring the NCT07213154 clinical trial?
NCT07213154 is sponsored by Emory University. The principal investigator is Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR at Emory University Hospital/Winship Cancer Institute. The trial plans to enroll 10 participants.